Boston, MA 09/05/2014 (wallstreetpr) – Laboratory Corp. of America holdings (NYSE:LH) launched a new business called Enlighten Health Genomics today. It is based on the diagnostic potential of Next Generation Sequencing technology.
As part of LabCorp’s Enlighten HealthSM, Enlighten Health Genomics seeks to drive innovation for provider, as well as patient-facing services. It would also lead innovation in tools that are aimed at enhancing treatment related choices, lower healthcare expenses and better patient results.
Enlighten Health Genomics, which deploys LabCorp’s world-class facilities, together with a team comprising accomplished geneticists, aims at offering state-of-the-art diagnostic provisions, NGS analysis and interpretation, and educated genetic counseling. In this context, Laboratory Corp. Of America Holdings (NYSE:LH)’s Chairman and Chief Executive Officer, David P. King, said that the division forms an important part of the company’s scheme to use its unique assets, while generating new revenue sources from its core capabilities. In addition, Enlighten Health Genomics would also play a vital role in differentiating the company from others in the field. He further said that the launch of the new business would assist in developing Enlighten Health, which is LabCorp’s initiative to develop novel tools and solutions to enhanced patient healthcare.
Enlighten Health Genomics also plans to introduce ExomeReveal later this year. It would offer a completely new testing service for exome sequencing. The initiative is line with the increasing evidence that supports early genetic diagnosis with the pretext that it helps in improving clinical results. ExomeRevea would hence offer provisions for genome-wide interpretation for young children suffering from extreme childhood genetic diseases. It would also provide more diagnostic data for other patients also, belonging to varied age groups.
According to David Goldstein, genetic professor at the Duke University, genome of patients in whom serious genetic conditions have been noticed, need a thorough interpretation. Goldstein will be the Chairperson of the Scientific Advisory Board of Enlighten Health Genomics.
